Which has higher valuation & earnings, GKOS or DXCM?

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 17.96 -$187.69M -$3.25 N/A DexCom $4.97B 6.58 $836.30M $2.53 34.24

Is GKOS or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% DexCom 20.12% 35.94% 14.75%

Does the media prefer GKOS or DXCM?

In the previous week, DexCom had 5 more articles in the media than Glaukos. MarketBeat recorded 8 mentions for DexCom and 3 mentions for Glaukos. Glaukos' average media sentiment score of 1.01 beat DexCom's score of 0.82 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GKOS or RMD?

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 17.96 -$187.69M -$3.25 N/A ResMed $5.65B 5.67 $1.52B $10.43 21.30

Is GKOS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% ResMed 26.94% 25.58% 18.89%

Does the media refer more to GKOS or RMD?

In the previous week, ResMed had 2 more articles in the media than Glaukos. MarketBeat recorded 5 mentions for ResMed and 3 mentions for Glaukos. ResMed's average media sentiment score of 1.12 beat Glaukos' score of 1.01 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GKOS or GEHC?

In the previous week, GE HealthCare Technologies had 16 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for GE HealthCare Technologies and 3 mentions for Glaukos. Glaukos' average media sentiment score of 1.01 beat GE HealthCare Technologies' score of 0.79 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GKOS or PHG?

Glaukos presently has a consensus price target of $180.54, suggesting a potential upside of 16.82%. Given Glaukos' stronger consensus rating and higher possible upside, equities research analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.80 Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, GKOS or PHG?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 17.96 -$187.69M -$3.25 N/A Koninklijke Philips $20.17B 1.22 $1.01B $1.36 18.36

Does the media favor GKOS or PHG?

In the previous week, Glaukos had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Glaukos and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.03 beat Glaukos' score of 1.01 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, STE or GKOS?

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $6.04B 3.37 $782.30M $8.18 25.52 Glaukos $507.44M 17.96 -$187.69M -$3.25 N/A

Is STE or GKOS more profitable?

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.34% 14.34% 9.66% Glaukos -30.68% -6.37% -4.78%

Does the media favor STE or GKOS?

In the previous week, Glaukos had 2 more articles in the media than STERIS. MarketBeat recorded 3 mentions for Glaukos and 1 mentions for STERIS. Glaukos' average media sentiment score of 1.01 beat STERIS's score of 0.47 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$154.55 -0.33 (-0.22%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$154.02 -0.52 (-0.34%)

As of 09/25/2026 07:30 PM Eastern

Compare

GKOS vs. DXCM, RMD, GEHC, PHG, and STE

Should you buy Glaukos stock or one of its competitors? Glaukos's main competitors and comparable companies include DexCom (DXCM), ResMed (RMD), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Glaukos compare to DexCom?

Glaukos (NYSE:GKOS) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Glaukos currently has a consensus target price of $180.54, indicating a potential upside of 16.82%. DexCom has a consensus target price of $89.08, indicating a potential upside of 2.84%. Given Glaukos' higher probable upside, equities research analysts clearly believe Glaukos is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
DexCom	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, DexCom had 5 more articles in the media than Glaukos. MarketBeat recorded 8 mentions for DexCom and 3 mentions for Glaukos. Glaukos' average media sentiment score of 1.01 beat DexCom's score of 0.82 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	17.96	-$187.69M	-$3.25	N/A
DexCom	$4.97B	6.58	$836.30M	$2.53	34.24

Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
DexCom	20.12%	35.94%	14.75%

Summary

DexCom beats Glaukos on 12 of the 17 factors compared between the two stocks.

How does Glaukos compare to ResMed?

Glaukos (NYSE:GKOS) and ResMed (NYSE:RMD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
ResMed	26.94%	25.58%	18.89%

In the previous week, ResMed had 2 more articles in the media than Glaukos. MarketBeat recorded 5 mentions for ResMed and 3 mentions for Glaukos. ResMed's average media sentiment score of 1.12 beat Glaukos' score of 1.01 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos currently has a consensus target price of $180.54, suggesting a potential upside of 16.82%. ResMed has a consensus target price of $241.69, suggesting a potential upside of 8.77%. Given Glaukos' stronger consensus rating and higher probable upside, analysts plainly believe Glaukos is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Glaukos has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	17.96	-$187.69M	-$3.25	N/A
ResMed	$5.65B	5.67	$1.52B	$10.43	21.30

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ResMed beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

GE HealthCare Technologies has a net margin of 9.33% compared to Glaukos' net margin of -30.68%. GE HealthCare Technologies' return on equity of 20.12% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
GE HealthCare Technologies	9.33%	20.12%	5.74%

Glaukos presently has a consensus target price of $180.54, suggesting a potential upside of 16.82%. GE HealthCare Technologies has a consensus target price of $78.39, suggesting a potential upside of 17.65%. Given GE HealthCare Technologies' higher probable upside, analysts plainly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.50

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	17.96	-$187.69M	-$3.25	N/A
GE HealthCare Technologies	$20.63B	1.46	$2.08B	$4.36	15.28

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

In the previous week, GE HealthCare Technologies had 16 more articles in the media than Glaukos. MarketBeat recorded 19 mentions for GE HealthCare Technologies and 3 mentions for Glaukos. Glaukos' average media sentiment score of 1.01 beat GE HealthCare Technologies' score of 0.79 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Glaukos (NYSE:GKOS) and Koninklijke Philips (NYSE:PHG) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Glaukos had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 3 mentions for Glaukos and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.03 beat Glaukos' score of 1.01 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Glaukos presently has a consensus price target of $180.54, suggesting a potential upside of 16.82%. Given Glaukos' stronger consensus rating and higher possible upside, equities research analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	17.96	-$187.69M	-$3.25	N/A
Koninklijke Philips	$20.17B	1.22	$1.01B	$1.36	18.36

Glaukos has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Koninklijke Philips has a net margin of 6.30% compared to Glaukos' net margin of -30.68%. Koninklijke Philips' return on equity of 14.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Koninklijke Philips	6.30%	14.38%	5.96%

Summary

Koninklijke Philips beats Glaukos on 8 of the 15 factors compared between the two stocks.

How does Glaukos compare to STERIS?

STERIS (NYSE:STE) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.34%	14.34%	9.66%
Glaukos	-30.68%	-6.37%	-4.78%

STERIS has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$6.04B	3.37	$782.30M	$8.18	25.52
Glaukos	$507.44M	17.96	-$187.69M	-$3.25	N/A

In the previous week, Glaukos had 2 more articles in the media than STERIS. MarketBeat recorded 3 mentions for Glaukos and 1 mentions for STERIS. Glaukos' average media sentiment score of 1.01 beat STERIS's score of 0.47 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.7% of STERIS shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

STERIS presently has a consensus price target of $271.33, suggesting a potential upside of 30.00%. Glaukos has a consensus price target of $180.54, suggesting a potential upside of 16.82%. Given STERIS's higher possible upside, equities analysts clearly believe STERIS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

STERIS beats Glaukos on 9 of the 16 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.11B	$5.56B	$7.33B	$22.98B
Dividend Yield	N/A	1.79%	2.52%	3.68%
P/E Ratio	-47.55	25.31	275.82	28.00
Price / Sales	17.96	72.33	640.25	88.78
Price / Cash	N/A	32.91	79.52	41.27
Price / Book	13.53	5.77	10.44	4.66
Net Income	-$187.69M	$151.55M	$3.51B	$1.07B
7 Day Performance	-5.41%	-0.97%	-1.31%	-1.12%
1 Month Performance	-15.07%	-4.40%	-4.61%	-5.10%
1 Year Performance	93.30%	7.68%	15.01%	7.73%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	2.6429 of 5 stars	$154.55 -0.2%	$180.54 +16.8%	+93.3%	$9.11B	$507.44M	N/A	1,094	Positive News Analyst Forecast
DXCM DexCom	3.3601 of 5 stars	$89.17 -0.2%	$89.08 -0.1%	+29.1%	$33.72B	$4.66B	35.25	11,000
RMD ResMed	3.7323 of 5 stars	$223.44 -0.7%	$241.69 +8.2%	-17.9%	$32.46B	$5.65B	21.42	11,370	Positive News
GEHC GE HealthCare Technologies	4.3837 of 5 stars	$64.81 +1.1%	$77.73 +19.9%	-8.0%	$28.97B	$20.63B	14.86	54,000	Dividend Increase Analyst Forecast Gap Up
PHG Koninklijke Philips	2.968 of 5 stars	$24.92 +1.0%	N/A	-6.8%	$24.26B	$20.17B	18.36	65,340	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors